Kymera Therapeutics, Inc.
KYMR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815442
In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 276 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $93.3M in total
- 8
- 13F holdersQ2 2026, +22 vs. previous quarter
- 276
- 13F valueReported value at the end of Q2 2026
- $11.1B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding KYMR, Q2 2026
No superinvestor reported holding KYMR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Kymera Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 (view filing)6:00 PM ET | Sep 4 | Same day | Adams BrianChief Legal Officer | SSale | −6.37K | $116.83 | −$744.3K | −11.3%50.3K after | 3 lots |
| Jul 7, 2026 (view filing)8:00 PM ET | Jul 7 | Same day | Mainolfi NelloChief Executive Officer | SSale | −50.0K | $119.00 | −$5.95M | −7.0%666.6K after | 10b5-1 |
| Jul 2, 2026 (view filing)6:30 PM ET | Jun 30 | 2 days | Jacobs Bruce N.Chief Financial Officer | SSale | −77.1K | $114.96 | −$8.86M | −23.9%244.9K after | 8 lots10b5-1 |
| Jul 2, 2026 (view filing)6:30 PM ET | Jul 1 | 1 day | Goodman NoahChief Business Officer | SSale | −3.39K | $114.29 | −$387.3K | −6.7%47.2K after | 10b5-1 |
| Jul 2, 2026 (view filing)6:30 PM ET | Jul 1 | 1 day | Mainolfi NelloChief Executive Officer | SSale | −80.0K | $115.29 | −$9.22M | −10.7%666.6K after | 5 lots10b5-1 |
| Jul 2, 2026 (view filing)5:39 PM ET | Jun 29 | 3 days | Booth BruceDirector | SSale | −76.7K | $108.05 | −$8.28M | −14.2%462.9K after | Amended14 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Booth BruceDirector | SSale | −31.3K | $109.48 | −$3.42M | −6.3%461.8K after | 8 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26-29 | 4 days | Booth BruceDirector | SSale | −513.2K | $110.01 | −$56.5M | −52.4%466.1K after | 30 lots10b5-1 |
| Jun 26, 2026 (view filing)6:48 PM ET | Jun 26 | Same day | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | SSaleCommon Stock, $0.0001 par value | −1.58M | $106.50 | −$168.1M | −86.8%240.1K after | 3 lots |
| Jun 26, 2026 (view filing)6:48 PM ET | Jun 26 | Same day | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | SSaleCommon Stock, $0.0001 par value | −51.9K | $106.50 | −$5.52M | −39.7%78.8K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Kymera Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 12,349,256 | $1.42B | 0.06% | +649,306+5.5% | Added |
| Baker Bros. Advisors LP | 8,657,242 | $992.7M | 4.97% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 7,474,747 | $857.1M | 7.70% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 7,112,980 | $815.6M | 0.08% | +1,052,133+17.4% | Added |
| T. Rowe Price Investment Management, Inc. | 6,257,261 | $717.5M | 0.47% | +792,264+14.5% | Added |
| BlackRock, Inc. | 5,538,210 | $635.1M | 0.01% | +477,334+9.4% | Added |
| BVF Inc | 3,872,052 | $444.0M | 11.35% | −1,630,658−29.6% | Reduced |
| Wellington Management Group LLP | 3,675,028 | $421.4M | 0.07% | −214,659−5.5% | Reduced |
| Vanguard Portfolio Management LLC | 2,992,193 | $343.1M | 0.02% | +118,137+4.1% | Added |
| Siren, L.L.C. | 2,935,830 | $336.7M | 6.83% | −251,000−7.9% | Reduced |